Friday 6 November 2026 Export IMVT’s income statement to Excel — free account

Immunovant, Inc.

IMVT Healthcare Biotechnology

EPS: −5.63%
Free cash flow: −5.96%

Quarter to June 2026, against a year earlier

Insider buying

30.53 2.14 +7.54%

Follow IMVT

Alert me

Market cap: $5.9B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Valuation Filings

Immunovant, Inc. 10-Q filed Aug 6, 2026

Fiscal Q1 2027 · Period ended Jun 30, 2026 · Filed Aug 6, 2026 · accepted 7:29 AM ET · Document on sec.gov · Filing index

Red flags

Share dilution Aug 6, 2026
Shares outstanding rose 18.5% in a year, to 206.6 million

10-Q filed Aug 6, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors: 40 added; every paragraph is new since the annual report